BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27210889)

  • 1. A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinson's disease.
    Noor NA; Mohammed HS; Mourad IM; Khadrawy YA; Aboul Ezz HS
    Life Sci; 2016 Jun; 155():174-9. PubMed ID: 27210889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease.
    Kumari R; Kumar JB; Luthra PM
    Neurosci Lett; 2015 Mar; 589():191-5. PubMed ID: 25528406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
    Jin F; Wu Q; Lu YF; Gong QH; Shi JS
    Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease.
    Khan MM; Ahmad A; Ishrat T; Khan MB; Hoda MN; Khuwaja G; Raza SS; Khan A; Javed H; Vaibhav K; Islam F
    Brain Res; 2010 Apr; 1328():139-51. PubMed ID: 20167206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.
    Requejo C; Ruiz-Ortega JA; Cepeda H; Sharma A; Sharma HS; Ozkizilcik A; Tian R; Moessler H; Ugedo L; Lafuente JV
    Mol Neurobiol; 2018 Jan; 55(1):286-299. PubMed ID: 28840482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of (-)-sesamin on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and dopaminergic neuronal cells of Parkinson's disease rat models.
    Park HJ; Zhao TT; Lee KS; Lee SH; Shin KS; Park KH; Choi HS; Lee MK
    Neurochem Int; 2015; 83-84():19-27. PubMed ID: 25747493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA.
    Lorenc-Koci E; Czarnecka A; Lenda T; Kamińska K; Konieczny J
    Neurochem Int; 2013 Dec; 63(8):790-804. PubMed ID: 24090640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
    Dabbeni-Sala F; Di Santo S ; Franceschini D; Skaper SD; Giusti P
    FASEB J; 2001 Jan; 15(1):164-170. PubMed ID: 11149904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavior and oxidative stress parameters in rats subjected to the animal's models induced by chronic mild stress and 6-hydroxydopamine.
    Tuon T; Meirelles SS; de Moura AB; Rosa T; Borba LA; Botelho MEM; Abelaira HM; de Mathia GB; Danielski LG; Fileti ME; Petronilho F; Ignácio ZM; Quevedo J; Réus GZ
    Behav Brain Res; 2021 May; 406():113226. PubMed ID: 33684423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
    Konieczny J; Czarnecka A; Kamińska K; Lenda T; Nowak P
    Behav Brain Res; 2015 Apr; 283():203-14. PubMed ID: 25655509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
    J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
    Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
    Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease.
    Smith MP; Cass WA
    Neuroscience; 2007 Feb; 144(3):1057-66. PubMed ID: 17110046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease.
    Smith MP; Cass WA
    Neurosci Lett; 2007 Feb; 412(3):259-63. PubMed ID: 17125923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson's disease induced by reserpine.
    Tharwat EK; Abdelaty AO; Abdelrahman AI; Elsaeed H; Elgohary A; El-Feky AS; Ebrahim YM; Sakraan A; Ismail HA; Khadrawy YA; Aboul Ezz HS; Noor NA; Fahmy HM; Mohammed HS; Mohammed FF; Radwan NM; Ahmed NA
    Metab Brain Dis; 2023 Jun; 38(5):1513-1529. PubMed ID: 36847968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.